Androgen deficiency is associated with a better prognosis in glioblastoma
Abstract Background The androgen receptor (AR) has been demonstrated to play a role in the pathogenesis of glioblastoma; however, the implications of circulating testosterone levels in the biology of glioblastoma remain unknown. Aim This study aimed to analyze the association between circulating tes...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-01-01
|
| Series: | European Journal of Medical Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40001-024-01648-3 |
| _version_ | 1797350072515559424 |
|---|---|
| author | Helga Fariña-Jerónimo Rita Martín-Ramírez Rebeca González-Fernández Lilian Medina Antonia de Vera Pablo Martín-Vasallo Julio Plata-Bello |
| author_facet | Helga Fariña-Jerónimo Rita Martín-Ramírez Rebeca González-Fernández Lilian Medina Antonia de Vera Pablo Martín-Vasallo Julio Plata-Bello |
| author_sort | Helga Fariña-Jerónimo |
| collection | DOAJ |
| description | Abstract Background The androgen receptor (AR) has been demonstrated to play a role in the pathogenesis of glioblastoma; however, the implications of circulating testosterone levels in the biology of glioblastoma remain unknown. Aim This study aimed to analyze the association between circulating testosterone levels and the prognosis of patients with glioblastoma. Methods Forty patients with primary glioblastoma were included in the study. The main prognostic endpoint was progression-free survival (PFS). Circulating testosterone levels were used to determine the state of androgen deficiency (AD). AR expression was analyzed by reverse-transcriptase polymerase chain reaction, Western blot, and immunofluorescence. Survival analysis was performed using the log-rank test and univariate and multivariate Cox regression analysis. Results Most of the patients showed AR expression, and it was mainly located in the cytoplasm, as well as in the nucleus of tumor cells. Patients with AD presented a better PFS than those patients with normal levels (252.0 vs. 135.0 days; p = 0.041). Furthermore, normal androgenic status was an independent risk factor for progression in a multivariate regression model (hazard ratio = 6.346; p = 0.004). Conclusion Circulating testosterone levels are associated with the prognosis of glioblastoma because patients with AD show a better prognosis than those with normal androgenic status. |
| first_indexed | 2024-03-08T12:39:34Z |
| format | Article |
| id | doaj.art-8f66c814e7724040be05b7d74711f2de |
| institution | Directory Open Access Journal |
| issn | 2047-783X |
| language | English |
| last_indexed | 2024-03-08T12:39:34Z |
| publishDate | 2024-01-01 |
| publisher | BMC |
| record_format | Article |
| series | European Journal of Medical Research |
| spelling | doaj.art-8f66c814e7724040be05b7d74711f2de2024-01-21T12:14:59ZengBMCEuropean Journal of Medical Research2047-783X2024-01-0129111210.1186/s40001-024-01648-3Androgen deficiency is associated with a better prognosis in glioblastomaHelga Fariña-Jerónimo0Rita Martín-Ramírez1Rebeca González-Fernández2Lilian Medina3Antonia de Vera4Pablo Martín-Vasallo5Julio Plata-Bello6Neurosurgery Department, Hospital Universitario de CanariasMolecular Biology Department, University of La LagunaMolecular Biology Department, University of La LagunaBiochemistry Laboratory, Hospital Universitario de CanariasBiochemistry Laboratory, Hospital Universitario de CanariasMolecular Biology Department, University of La LagunaNeurosurgery Department, Hospital Universitario de CanariasAbstract Background The androgen receptor (AR) has been demonstrated to play a role in the pathogenesis of glioblastoma; however, the implications of circulating testosterone levels in the biology of glioblastoma remain unknown. Aim This study aimed to analyze the association between circulating testosterone levels and the prognosis of patients with glioblastoma. Methods Forty patients with primary glioblastoma were included in the study. The main prognostic endpoint was progression-free survival (PFS). Circulating testosterone levels were used to determine the state of androgen deficiency (AD). AR expression was analyzed by reverse-transcriptase polymerase chain reaction, Western blot, and immunofluorescence. Survival analysis was performed using the log-rank test and univariate and multivariate Cox regression analysis. Results Most of the patients showed AR expression, and it was mainly located in the cytoplasm, as well as in the nucleus of tumor cells. Patients with AD presented a better PFS than those patients with normal levels (252.0 vs. 135.0 days; p = 0.041). Furthermore, normal androgenic status was an independent risk factor for progression in a multivariate regression model (hazard ratio = 6.346; p = 0.004). Conclusion Circulating testosterone levels are associated with the prognosis of glioblastoma because patients with AD show a better prognosis than those with normal androgenic status.https://doi.org/10.1186/s40001-024-01648-3GlioblastomaTestosteroneAndrogen receptorPrognosis |
| spellingShingle | Helga Fariña-Jerónimo Rita Martín-Ramírez Rebeca González-Fernández Lilian Medina Antonia de Vera Pablo Martín-Vasallo Julio Plata-Bello Androgen deficiency is associated with a better prognosis in glioblastoma European Journal of Medical Research Glioblastoma Testosterone Androgen receptor Prognosis |
| title | Androgen deficiency is associated with a better prognosis in glioblastoma |
| title_full | Androgen deficiency is associated with a better prognosis in glioblastoma |
| title_fullStr | Androgen deficiency is associated with a better prognosis in glioblastoma |
| title_full_unstemmed | Androgen deficiency is associated with a better prognosis in glioblastoma |
| title_short | Androgen deficiency is associated with a better prognosis in glioblastoma |
| title_sort | androgen deficiency is associated with a better prognosis in glioblastoma |
| topic | Glioblastoma Testosterone Androgen receptor Prognosis |
| url | https://doi.org/10.1186/s40001-024-01648-3 |
| work_keys_str_mv | AT helgafarinajeronimo androgendeficiencyisassociatedwithabetterprognosisinglioblastoma AT ritamartinramirez androgendeficiencyisassociatedwithabetterprognosisinglioblastoma AT rebecagonzalezfernandez androgendeficiencyisassociatedwithabetterprognosisinglioblastoma AT lilianmedina androgendeficiencyisassociatedwithabetterprognosisinglioblastoma AT antoniadevera androgendeficiencyisassociatedwithabetterprognosisinglioblastoma AT pablomartinvasallo androgendeficiencyisassociatedwithabetterprognosisinglioblastoma AT julioplatabello androgendeficiencyisassociatedwithabetterprognosisinglioblastoma |